Press releases

Ultromics receives an investment from the AHA Go Red for Women Venture Fund to address heart failure with preserved ejection fraction, a condition affecting millions of women.

Ultromics’ new multi-center study shows its AI tool, EchoGo® Amyloidosis, can improve early detection of cardiac amyloidosis using routine heart ultrasounds, increasing referral accuracy and reducing unnecessary testing—helping more patients access life-saving therapies sooner.

Ultromics has been named a WIRED 2025 Trailblazer, recognized for pioneering AI in cardiovascular imaging. With its FDA-cleared EchoGo® platform, Ultromics is tackling the global heart failure crisis by enabling earlier diagnosis and transforming patient care.

Ultromics has been selected for Tech Nation’s prestigious Future Fifty 2025 programme, recognizing its AI-powered cardiovascular imaging platform, EchoGo®. Founded at the University of Oxford, Ultromics is scaling globally to close critical gaps in heart failure diagnosis and improve early detection across leading healthcare institutions.

New $55M Series C round fuels Ultromics' nationwide rollout of FDA-cleared AI that detects heart failure earlier from a single echo scan—helping clinicians catch HFpEF and cardiac amyloidosis before it's too late.

New study shows EchoGo® Amyloidosis, developed by Ultromics, Mayo Clinic and University of Chicago Medicine, detects cardiac amyloidosis with accuracy for a single echo view

EchoGo® Heart Failure now delivers a continuous probability score reflecting the likelihood of HFpEF to support clinical decision-making.

EchoGo® Heart Failure assigned to APC 5743 under the new Category III CPT code 0932T for outpatient HFpEF diagnosis

Ultromics granted FDA Breakthrough Device Designation for its Amyloidosis device

Study Confirms AI-Based Detection of HFpEF is Linked to Cardiac Outcomes

EchoGo® Featured in Hot Line and Late-Breaking Science Sessions at ESC Congress 2024

Ultromics announces new CPT III code to facilitate clinical reimbursement for EchoGo® Heart Failure.